Category
Transforming Healthcare Pricing: Implications of Trump’s Executive Order on Transparency
On February 25, 2025, President Donald J. Trump issued an Executive Order aimed at transforming healthcare pricing transparency. This directive requires the Departments of the Treasury, Labor, and Health and Human Services to implement regulations mandating that hospitals and insurers disclose actual, real-time pricing data, including the costs of… Read More
Video: Practical Strategies for Emerging, Small, and Mid-Size Companies
In the recently held Medicaid Drug Rebate Program (MDRP) Conference, a session titled Practical Strategies for Emerging, Small, and Mid-Size Companies offered essential insights for pharmaceutical companies navigating the complexities of expansion, commercialization, and mergers & acquisitions. The session, led by RLDatix Life Sciences’ Katie Johnson, Senior Director of Revenue… Read More
5 Stats to Watch in State Price Transparency
In Life Sciences, price transparency is a basic regulatory requirement. It’s also a strategic imperative that influences market access, patient affordability, and company reputation. Across the United States, state-specific regulations play a pivotal role in shaping how price transparency is implemented and governed. These regulations are designed to ensure that… Read More
7 Tips for Managing Multi-State Drug Pricing Compliance in Life Sciences
Navigating the regulatory landscape of multi-state pricing compliance in the Life Sciences sector can be challenging. With different states enforcing varying regulations on drug pricing and transparency, companies need a robust strategy to ensure compliance and mitigate risks. Here are seven practical tips to help manage multi-state pricing compliance effectively. Read More